Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 8/20 | 0.60 |
| ▸ | DPP4 | P27487 | 1/20 | 0.55 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.55 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.55 |
| ▸ | BACE1 | P56817 | 9/20 | 0.49 |
| ▸ | CTSD | P07339 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | BACE2 | Q9Y5Z0 | 2/20 | 0.48 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31195712 | 1.00 | FOLH1 (0.60) | FOLH1DPP4DPP8DPP9BACE1 | |
| SCHEMBL30784907 | 1.00 | FOLH1 (0.60) | FOLH1DPP4DPP8DPP9BACE1 | |
| SCHEMBL30676233 | 0.97 | FOLH1 (0.64) | FOLH1DPP4DPP8DPP9BACE1 | |
| SCHEMBL537147 | 0.97 | FOLH1 (0.64) | FOLH1DPP4DPP8DPP9BACE1 | |
| SCHEMBL537148 | 0.97 | FOLH1 (0.64) | FOLH1DPP4DPP8DPP9BACE1 | |
| SCHEMBL31233849 | 0.96 | FOLH1 (0.56) | FOLH1DPP4DPP8DPP9BACE1 | |
| SCHEMBL29655260 | 0.95 | FOLH1 (0.63) | FOLH1DPP4DPP8DPP9BACE1 | |
| SCHEMBL29400510 | 0.95 | FOLH1 (0.63) | FOLH1DPP4DPP8DPP9BACE1 | |
| SCHEMBL30480113 | 0.94 | FOLH1 (0.61) | FOLH1DPP4DPP8DPP9BACE1 | |
| SCHEMBL30430488 | 0.94 | FOLH1 (0.61) | FOLH1DPP4DPP8DPP9BACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220280579-A1 | Formulations for Prevention or Reduction of C. Difficile Infections | SPOREGEN LIMITED (GB) | 2022-09-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220280579-A1 | Formulations for Prevention or Reduction of C. Difficile Infections | SI, FABP2, CRY1 | FOLH1 2799/4885DPP4 1345/4885DPP8 780/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.